A new systematic review reveals promising results for oncolytic viral therapy in treating nonmelanoma skin cancers and ...

Oncolytic adenovirus was engineered for the forced ectopic delivery of peptide-MHC ligand of T cell receptors (TCRs) to ...

Merck & Co’s $394 million acquisition of Viralytics has stoked interest in oncolytic viruses, a class of drugs that have been in the shadow of the checkpoint inhibitors and CAR-T therapies that ...

Oncolytic viruses, once considered medical curiosities, are now cutting-edge tools in the fight against some of the most challenging cancers, like glioblastoma. These tiny engineered viruses ...